Phase II trial of pegylated interferon-α2b in patients with advanced renal cell carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Kidney

abstract

  • Pegylated IFN administered weekly has antitumor activity in patients with mRCC with predominantly good- and intermediate-risk features. This study suggests comparable efficacy and safety compared with standard IFN-alpha.

publication date

  • March 2008

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.3816/CGC.2008.n.004

PubMed ID

  • 18501079

Additional Document Info

start page

  • 25

end page

  • 30

volume

  • 6

number

  • 1